Deregulated protein tyrosine kinase activity is central to the pathogenesis of human cancers.
Targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) has transformed …

Chromosomal rearrangements that lead to oncogenic kinase activation are observed in
many epithelial cancers. These cancers express activated fusion kinases that drive the …

Bosutinib, a dual Src/Abl tyrosine kinase inhibitor (TKI), has shown potent activity against
chronic myeloid leukemia (CML). This phase 1/2 study evaluated the efficacy and safety of …

Our study is designed to assess if exosomes released from chronic myelogenous leukemia
(CML) cells may modulate angiogenesis. We have isolated and characterized the exosomes …

Theragnostics is a treatment strategy that combines therapeutics with diagnostics. It
associates both a diagnostic test that identifies patients most likely to be helped or harmed …

Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic
myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an …

The process of cell division or mitosis is highly complex and tightly regulated. During this
phase of the cell cycle two identical copies of DNA are completely separated by the …

Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic
myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report …

Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical
activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML) …

Abstract BACKGROUND. BCR‐ABL kinase domain (KD) mutations are detected in
approximately 45% of patients with imatinib‐resistant chronic myeloid leukemia. Patterns of …